- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.10. | Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup | 2 | MarketBeat | ||
| 24.09. | Inhibrx's Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall? | 1 | Insider Monkey | ||
| 18.09. | Citizens reiterates Market Perform on Inhibrx Biosciences stock | 1 | Investing.com | ||
| 18.09. | Inhibrx Biosciences: Citizens bestätigt "Market Perform"-Rating | 1 | Investing.com Deutsch | ||
| 09.09. | Inhibrx, Eikon rise after insider buying | 2 | Seeking Alpha | ||
| 09.09. | H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy | 2 | Investing.com | ||
| 08.09. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.09. | Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates | 1 | Benzinga.com | ||
| INHIBRX BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 08.09. | Inhibrx CEO says progression-free survival data leave 'no question' about OX40 agonist's durability | 2 | FierceBiotech | ||
| 08.09. | Inhibrx cancer therapy outperforms Merck's Keytruda in mid-stage trial | 8 | Seeking Alpha | ||
| 08.09. | Positive Studiendaten zu Krebsmedikament beflügeln Inhibrx Aktie | 2 | Investing.com Deutsch | ||
| 08.09. | Inhibrx Biosciences, Inc.: Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study | 528 | PR Newswire | First OX40 agonist to demonstrate clinical benefit in a randomized study
INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression... ► Artikel lesen | |
| 27.08. | Citizens reiterates Market Perform on Inhibrx Biosciences stock | 2 | Investing.com | ||
| 21.08. | Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target | 1 | Investing.com | ||
| 21.08. | Stifel bekräftigt Kaufempfehlung für Inhibrx Biosciences mit Kursziel von 325 US-Dollar | 1 | Investing.com Deutsch | ||
| 13.08. | Inhibrx Biosciences GAAP EPS of -$2.34 beats by $0.05 | 1 | Seeking Alpha | ||
| 13.08. | Inhibrx Biosciences, Inc.: Inhibrx Reports Second Quarter 2026 Financial Results | 374 | PR Newswire | SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter... ► Artikel lesen | |
| 16.07. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Inhibrx expands credit facility to $500 million with Oxford | 3 | Investing.com | ||
| 15.06. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | -0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | -0,13 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus | ||
| KYMERA THERAPEUTICS | 136,60 | -0,03 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,160 | +0,04 % | Jones Trading initiates Beam Therapeutics stock coverage with buy rating | ||
| ENLIVEN THERAPEUTICS | 51,29 | +0,18 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update | Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents... ► Artikel lesen | |
| JANUX THERAPEUTICS | 12,040 | 0,00 % | Janux reports phase 1 data for autoimmune drug candidate JANX011 | ||
| RECURSION PHARMACEUTICALS | 3,550 | 0,00 % | Recursion Pharmaceuticals (NDQ:RXRX): Why Is Nvidia An Investor? Because Its AI Platform Could Change Drug Discovery, Or Could It? |
Das Unternehmen INHIBRX BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,00 (0,00 %) liegt der Kurs bei 90,61 Euro. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBRX BIOSCIENCES INC finden Sie auf Wallstreet Online.